WebRepare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to developing novel medicines. Web13 mei 2024 · Despite the discovery of RAS oncogenes in human tumor DNA 40 years ago, the development of effective targeted therapies directed against RAS has lagged behind those more successful advancements in the field of therapeutic tyrosine kinase inhibitors targeting other oncogenes such as EGFR, ALK, and ROS1. The discoveries that (1) …
IDEAYA Announces Presentations at AACR Annual Meeting 2024 …
Web7 mrt. 2024 · IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of … WebIDEAYA Values. Passionate Commitment. We believe in our goals; we are agile and persevere. Fearless Innovation. We look for novel approaches regardless of the challenge. Courageous Integrity. We do not hesitate to do what is right. Respectful Teamwork. Together we create a transparent and cohesive work environment. homes for sale in arab al
IPO早知道 Vividion Therapeutics：靶向转录因子的小分子药物公 …
Web11 dec. 2024 · IDEAYA Biosciences is an oncology specialist focused on precision medicine aiming to utilize molecular diagnostics to develop targeted therapeutics with a research … Web10 mei 2024 · Program Updates Key highlights for IDEAYA's pipeline programs include: IDE397 (MAT2A) IDEAYA is evaluating IDE397, a potent and selective small molecule … Web8 apr. 2024 · IDEAYA Biosciences (NASDAQ: IDYA) is a public, clinical-stage synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using DNA sequencing and other molecular diagnostics. hippolife of sweden